Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 69

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 69
---
 and investments in U.S. Treasury bills.

17

Results of Operations

The following tables summarize our results of operations for the three and six months ended June 30, 2025 and 2024 (in thousands):

Three Months Ended June 30,Six Months Ended June 30,20252024Change20252024ChangeOperating expenses:Research and development$1,541 $3,563 $(2,022)$3,730 $6,378 $(2,648)General and administrative1,164 1,506 (342)2,369 3,434 (1,065)Total operating expenses2,705 5,069 (2,364)6,099 9,812 (3,713)Loss from operations(2,705)(5,069)2,364 (6,099)(9,812)3,713 Interest income17 98 (81)33 238 (205)Other income, net151 - 151 182 - 182 Net loss$(2,537)$(4,971)$2,434 $(5,884)$(9,574)$3,690 

Three Months Ended June 30,Six Months Ended June 30,20252024Change20252024ChangeResearch and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $7 $(7)$— $61 $(61)INVINCIBLE-2 Study (Phase 2 Breast)— 117 (117)— 221 (221)INVINCIBLE-3 Study (Phase 3 Sarcoma)788 1,970 (1,182)2,383 3,388 (1,005)INVINCIBLE-4 Study (Phase 2 Breast)134 315 (181)197 315 (118)Other14 58 (44)14 58 (44)Clinical trial expenses936 2,467 (1,531)2,594 4,043 (1,449)Contract manufacturing6 417 (411)29 631 (602)Salaries and benefits related costs292 448 (156)622 842 (220)Consulting & Other44 14 30 62 79 (17)Stock-based compensation263 217 46 423 783